Please login to the form below

Not currently logged in
Email:
Password:

Odefsey

This page shows the latest Odefsey news and features for those working in and with pharma, biotech and healthcare.

Gilead gets EU nod for TAF-based triple therapy for HIV

Gilead gets EU nod for TAF-based triple therapy for HIV

Once-daily, single-tablet Odefsey reduces risks of side effects such as renal and bone toxicity. ... Gilead Sciences has added to its portfolio of HIV drugs in Europe after getting EMA approval for Odefsey, a three-drug combination based on its new

Latest news

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics